

# Index

- abortion, adenomyosis and, 29  
 acupuncture, 46, 47–8  
   anaesthesia use with, 99–100  
   CPR and, 47  
   ET and, 47–8  
 adenomyosis  
   abortion rates with, 29  
   clinical features of, 28  
   cystic, 29–30  
   defined, 28  
   diagnosis of, 28  
     with MRI, 28  
   discovery of, 28  
   endometriosis and, 29  
   incidence rates for, 28  
   infertility and, 28  
   IVF and, 29  
     failure of, 162  
   JZ hyperplasia, 28, 29, 30  
   pregnancy rates with, 29  
   treatment strategies, 29–30  
     management recommendations, 30  
     through surgery, 29–30  
     ultrasound for, 155  
 adequate follicular recruitment, 110–12  
   cycles of, 112  
   hCG levels, 111–12  
   management of, 112  
   progesterone bioavailability, 111–12  
 adjuvant therapies, 16–17  
   androgens in, 16–17  
   growth hormones in, 17  
 AFC. *See* antral follicle count  
 aging, for males  
   ART consultations influenced by, 32  
   paternity influenced by, 33  
   sperm quality and, 32–4  
 AH. *See* assisted hatching  
 albumin, 95  
 alcohol consumption, IVF failure and, 159  
 alfentanil, 99  
 ALSPAC. *See* Avon Longitudinal Study of Pregnancy and Childhood  
 AMH levels. *See* anti-Müllerian hormone levels  
 amnion graft, 43  
 anaesthesia use  
   acupuncture with, 99–100  
   advantages of, 99  
   clinical pregnancy rates, 98  
   disadvantages of, 99  
   guidelines for, 97  
   management of, 98–100  
     for general anaesthesia, 99  
     for local/regional anaesthesia, 99  
     under MAC, 98–9  
   OHSS and, 98, 100  
   postoperative care, 100  
     for fever management, 100  
     for home readiness, 100  
     for hypotension, 100  
     for nausea and vomiting, 100  
     pain management, 100  
     for urinary retention, 100  
   preoperative considerations, 97–8  
     anxiety issues, 98  
     preexisting illness, 98  
     subfertility causes, 97  
 androgens, in adjuvant therapies, 16–17  
 aneuploidy screening. *See also* preimplantation genetic screening  
   poor embryo development and, 170–1  
 animal studies, for intrauterine fluid issues, 80  
 antagonist stimulation protocols, 11  
 antibiotics, for IUAs, 43  
 anti-Müllerian hormone (AMH)  
   levels, 81  
   FSH, for poor responders to GnRH therapy, 15, 16  
   OHSS and, 92  
 antral follicle count (AFC), 156  
 anxiety, 98  
 Asherman's syndrome. *See also* intrauterine adhesions  
   thin endometrium and, 76  
 aspiration pumps. *See* electric oocyte aspiration pump; manual aspiration pump  
 aspirin, 17, 77  
   for OHSS, 94  
 assisted hatching (AH), 160  
 assisted reproduction treatment (ART), 46–7. *See also in vitro* fertilization; transvaginal ultrasound; ultrasound  
   culture media and, 63  
   future of, 209–11  
     key advances in, 209  
   intramural fibroids and, 8  
   IUI, 46–7  
   for older males  
     age criteria for, 32  
     clinical reasons for, 32  
     equipment for, 34  
     information sheets for, 34  
     ‘must have’ protocols, 34  
     strategies for, 34  
   patient's perspective on  
     on egg collection day, 5  
     on ET, 5–6  
     IVF costs and, 6  
 Avanafil, 125  
 Avon Longitudinal Study of Pregnancy and Childhood (ALSPAC), 33  
 bifollicular recruitment, 110  
 bilateral endometrioma, 36  
 blastocyst transfer, 160  
 blastocyte-stage transfer, 64  
 blastomere biopsy, 149  
 body mass index (BMI), 118  
   IVF failure and, 159  
 Bologna Criteria, 14, 15  
 Bolt, Usain, 181  
 bromocriptine, 94  
 Brown, Louise, 1, 209  
 business plans. *See* financial models  
 cabergoline, 94  
 calcium infusions, 95  
 CAM. *See* Complementary and Alternative medicine  
 cancer patients  
   fertility preservation methods, for boys, 26  
   fertility preservation methods, for girls, 24, 26  
   through ovarian tissue cryopreservation, 25

## Index

- fertility preservation methods, for men, 26  
 fertility preservation methods, for women, 24–6  
   with GnRH agonists, 24–5  
   through oocyte cryopreservation, 25–6  
   through ovarian tissue cryopreservation, 25  
   through ovary transposition, 25  
*Candida albicans*, 144–5  
 CAT. *See* chlamydia antibody testing  
 cervical dilatation, 120  
 cervix, ET and  
   appearance of, 118  
   canal, 119  
   mucus and blood in, 118–19  
 Channon, Sue, 212–14  
 Chinese herbal medicine (CHM), 46, 48  
   IVF and, 46–7  
   WS-TCM, 48  
 chlamydia antibody testing (CAT), 60–1  
   PID and, 61  
 CHM. *See* Chinese herbal medicine  
 clinical pregnancy rate (CPR), 47  
 clomiphene nitrate, 76  
 coasting, OHSS and, 12  
 COCP. *See* combined oral contraceptive pill  
 co-enzyme Q, 17  
 COH. *See* controlled ovarian hyperstimulation  
 combined oral contraceptive pill (COCP), 76  
 Complementary and Alternative Medicine (CAM), IVF and  
   acupuncture, 46, 47–8  
   CPR and, 47  
   ET and, 47–8  
   CHM, 46, 48  
   IVF and, 46–7  
   WS-TCM, 48  
   intervention strategies, 48–9  
     follicle ripening, 49  
     oocyte retrieval, 49  
     ovarian follicle stimulation, 49  
 consent. *See also* informed consent  
   for ovarian tissue cryopreservation, 21  
 controlled ovarian hyperstimulation (COH), 76  
   FF and, 167  
 Cook intrauterine balloon, 43  
 Cooke, Ian, 1–4  
 corifollitropin alfa, 16  
 Costa Rica, IVF in, 3  
 costs. *See* financial models  
 counselling, for poor responders, 17–18  
   for couples, 17  
 CPR. *See* clinical pregnancy rate  
 cryopreservation. *See also* embryo  
   cryopreservation; oocyte  
   cryopreservation; ovarian  
   tissue cryopreservation  
   OHSS and, 12  
   PGD/PGS management and, 151  
   sperm, 124  
 cryptozoospermia, 165  
 culture media, human embryo  
   in ART, 63  
   criteria for choice of, 64–5  
     culture environment, 64  
     embryo manipulation, 64–5  
     physical infrastructure, 64  
     technical infrastructure, 64  
   development approaches, 64–5  
   future prospects for, 65  
   historical development of, 63  
   KPI and, 72  
   poor development as result of, 171–2  
   sequential  
     blastocyte-stage transfer, 64  
     defined, 63  
     single-step compared to, 63–4  
   single-step  
     blastocyte-stage transfer, 64  
     defined, 63  
     sequential compared to, 63–4  
 cystic adenomyosis, 29–30  
 danazol, 29  
 data collection, by research nurses, 192–3  
 difficult ET, 118  
   cervical dilatation, 120  
   past embryo transfer risks, 120  
   predictions of, 120–2  
   prevention strategies, 121–2  
 documentation, for ovarian tissue  
   cryopreservation, 22  
   audits of, 23  
 donor oocytes, 89  
 dosage regimes, for ovarian  
   stimulation protocols, 12–13  
   for GnRH, 12–13  
   SOP guidelines, 12  
 down-regulation stimulation  
   protocols, 16  
 Edwards, Robert, 209  
 egg collection. *See also* laparoscopic  
   egg retrieval; oocyte retrieval;  
   transvaginal ultrasound-  
   directed oocyte retrieval  
   patient's perspective on, 5  
   through TVOR, 104, 114–15  
   with TVOR, 104  
 ejaculatory function  
   normal, 123  
   retrograde, 125  
   risk factors for, 123  
 electric oocyte aspiration pump  
   functions of, 108  
   installation and set-up, 107–9  
   machine failure actions, 109  
   possible issues/solutions for, 108–9  
 electroejaculation, 125  
 Elonva Flare, 16  
 embryo cryopreservation, 2  
   downward trends for, investigation  
     of, 134  
   bias in, 134  
   data volume, 134  
   embryo demographics, 135  
   laboratory changes, 135  
   patient demographics, 134  
   upstream factors in, changes to, 135  
 in OHSS, 94  
 ovarian tissue cryopreservation  
   compared to, 19  
 poor survival after  
   corrective actions, 135–7  
   culture conditions and, 133  
   environmental issues and, 133  
   equipment issues and, 133  
   freezing/thawing issues, 132  
   human factors for, 133–4  
   investigation of, 132  
   operator protocols as factor in, 132–3  
   patient history as factor in, 132  
   preventative measures for, 135–7  
   processes and factors for, 133  
   reporting considerations for, 134  
 embryo development. *See also* culture  
   media; poor embryo  
   development  
   with endometrioma, 38  
   normal, 169  
 embryo transfer (ET). *See also* 'lost'  
   embryos  
   acupuncture and, 47–8  
   difficult, 118  
   cervical dilatation, 120  
   past embryo transfer risks, 120  
   predictions of, 120–2  
   prevention strategies, 121–2  
   early history of, 118  
   endometrial patterns, 75  
   ET catheter selection, 120  
   firm/soft catheters, 120  
   factors for, 118–20  
   bladder filling, 119–20  
   BMI, 118  
   cervical appearance, 118

- cervical canal, 119  
 cervical mucus and blood, 118–19  
 UCA, 119  
 utero-cervical angle, 119  
 FET, 76–7  
   luteal phase support and, 89, 90  
 intrauterine fluid issues and, 79, 82, 83  
 IUAS and, 44  
 IVF failure and, 161  
 ‘lost’ embryos in, 138–42  
   from accidents, 141  
   causes of, 139  
   from failure to follow processes, 140, 141  
   from moving between dishes, 138–41  
 mock, 121  
   stylet use, 121  
   tenaculum use, 121  
   timing of, 121  
 patient’s perspective on, 5–6  
 personal preference for, 120  
 processes for, 118  
 under sedation, 121  
 TMET, 121  
 ultrasound guidance, 120  
 empty follicle syndrome, 105  
 EMT. *See* endometrial thickness  
 endometrial perfusion therapies, 77  
 endometrial thickness (EMT), 74  
   clinical significance of, 74–5  
   TVS for, 80  
 endometrioma, endometriosis and adenomyosis and, 29  
 bilateral, 36  
 embryo development with, 38  
 management of, 36–8  
 oocyte retrieval with, 38  
 patient history with, 36  
 pregnancy and, 38  
 treatment options, 36–7  
   adverse effects of, 37  
   conservative, 36  
   ESHRE guidelines for, 36  
   individualisation of care, 37  
   medical, 36  
   with stimulation protocols, 37  
   with surgery, 36–7  
 TVOR and, 105  
 unilateral, 36  
 endometriotic cysts, 102  
 endometrium. *See also* thin endometrium  
   dating of, 74  
   EMT, 74  
   clinical significance of, 74–5  
   with IUAs, 44  
   patterns, 74  
   clinical significance, 75–6  
   ET, 75  
   polyps, 161  
   regeneration of, 43–4  
   sonographic measurement of, 74  
 EQA programmes. *See* external quality assurance programmes  
 EQC. *See* External Quality Control  
 erectile function  
   normal, 123  
   risk factors for, 123  
*Escherichia coli*, 144–5  
 ESHRE. *See* European Society of Human Reproduction and Embryology  
 estrogen therapy  
   for IUAs, 43–4  
   in luteal phase support, 89  
   for thin endometrium, 77  
 ET. *See* embryo transfer  
 ET catheters, 120  
   firm/soft catheters, 120  
 European Society of Human Reproduction and Embryology (ESHRE), 2  
   endometrioma treatment guidelines, 36  
   KPI recommendations, 66, 67  
   poor responders to GnRH, definitions of, 14  
 European Union Tissues and Cells Directive, 71  
 external quality assurance (EQA) programmes, 72  
 External Quality Control (EQC), 178  
 fallopian tubes, assessment of  
   with 3D ultrasound, 155–6  
   HyCoSy and, 155–6  
   with hydrosalpinges, 156  
   for patency, 155–6  
 falloscopy, 60  
   performance of, 60  
   risks with, 60  
 fentanyl, 99  
 fertilisation failure (FF)  
   clinical definitions of, 165–6  
   COH, 167  
   incidence rates, 165  
   individualisation of care, 167  
   lab environment changes, 166–7  
   male factors, 167  
   multidisciplinary input for, 167  
   peri-conception factors, 167  
   PFF, 165  
   polar bodies and, 165  
   TFF, 165–6, 167  
 fertility preservation methods, for  
   cancer patients  
   for boys, 26  
   for girls, 24, 26  
   through ovarian tissue cryopreservation, 25  
   for men, 26  
   for women, 24–6  
   with GnRH agonists, 24–5  
   through oocyte cryopreservation, 25–6  
   through ovarian tissue cryopreservation, 25  
   through ovary transposition, 25  
 fertility research, 191. *See also* research nurses  
   patient choice in, 194, 195  
   stakeholders in, 194  
 fertility/infertility centers. *See* financial models; marketing  
 fertiloscopy, 59–60  
   performance of, 60  
   risks with, 60  
 FET. *See* frozen embryo transfer  
 fever management, 100  
 FF. *See* fertilisation failure  
 financial models, for fertility/infertility centers  
   balance sheets, 203–4  
   building of, 204  
   definition of, 203  
   business plans, 197–9  
   development of, 197–8  
   profit and loss accounts, 198–9, 201  
   unit setup in, 198–9  
   for center setup, 203  
   costs of running centers, 203–3  
   for consumables, 202  
   operating costs, 202  
   investments in, 203  
   operational options, 205  
   profitability measures, 204, 205  
   revenues from services, 201  
   primary sources, 201  
   secondary sources, 202  
   tactical and strategic options, 206  
 Foley balloon therapy, 42  
 Foley catheter with balloon, 42  
 follicle ripening, 49  
 follicles. *See* primordial follicles  
 follicular flushing, 104  
 follicular recruitment, limited, 110–12  
   adequate, 110–12  
   cycles of, 112  
   hCG levels, 111–12  
   management of, 112  
   progesterone bioavailability, 111–12  
 bifollicular, 110  
   cycles of, 110  
   cancellation of, no follicular recruitment and, 110  
 monofollicular, 110

## Index

- follicular stimulating hormone (FSH),  
 11–12  
 OHSS and, 93–4  
 for poor responders to GnRH  
 therapy, 15, 16  
 frozen embryo transfer (FET), 76–7  
 luteal phase support and, 89, 90  
 FSH. *See* follicular stimulating  
 hormone
- gamete donation, 163  
 gas supply failure, in incubators, 127–8  
 identification of, 127–8  
 prevention of, 127  
 resolution of, 128  
 gatekeeper principle, 194  
 GcSF. *See* granulocyte colony  
 stimulating factor
- gentamycin, 143  
 globozoospermia, 165  
 gonadotrophin-releasing hormone  
 (GnRH), 12–13. *See also* poor  
 responders  
 in luteal phase support, 89, 90  
 OHSS and, 92–4  
 thin endometrium management  
 with, 77  
 for women with cancer, 24–5  
 granulocyte colony stimulating factor  
 (GcSF), 78  
 growth hormones, in adjuvant  
 therapies, 17
- hCG. *See* human chorionic  
 gonadotropin
- HES. *See* hydroxy-ethyl starch
- HF. *See* human factors
- home readiness, 100
- hormones  
 AMH levels, 81  
 OHSS and, 92  
 FSH, 11–12  
 OHSS and, 93–4  
 GcSF, 78  
 GnRH, 12–13. *See also* poor  
 responders  
 in luteal phase support, 89, 90  
 OHSS and, 92–4  
 thin endometrium management  
 with, 77  
 for women with cancer, 24–5  
 growth, in adjuvant therapies, 17  
 hCG, 77  
 adequate follicular recruitment  
 and, 111–12  
 luteal phase support and, 86, 89  
 OHSS, 93–4  
 LH, 86  
 in luteal phase support, 87  
 estrogen, 89  
 GnRH agonists, 89, 90  
 LH, 86  
 progesterone preparations, 86–9  
 protocols for, 89–90  
 progesterone, 86–9  
 adequate follicular recruitment  
 and, 111–12  
 in luteal phase support, 86–9  
 synthetic, 86  
 HSG. *See* hysterosalpingogram
- human chorionic gonadotropin  
 (hCG), 77  
 adequate follicular recruitment and,  
 111–12  
 luteal phase support and, 86, 89  
 OHSS, 93–4
- human embryo culture media. *See*  
 culture media
- human factors (HF)  
 after-action review, 184  
 checklists, 183–4  
 double checking, 184  
 environmental influences, 181–2  
 errors, 181  
 incident analysis, 184  
 in teamwork, 182–3  
 authority and, 182–3  
 leadership and, 182–3  
 variabilities in, 181–3
- Human Fertilisation and Embryology  
 Act (1991), UK, 2
- hyalobarrier, 43  
 hyaluronic acid, 43  
 HyCoSy. *See* hysterosalpingo-contrast-  
 sonography
- hydrosalpinges  
 causes of, 51  
 defined, 51  
 diagnosis of, 51–2  
 fallopian tube assessment and, 156  
 future research on, 53  
 intrauterine fluid issues and, 79–81  
 IVF and, 51–2  
 IVF failure and, 162  
 clinical trials, 162  
 treatment strategies, 51, 52–3  
 audits before, 53  
 with reduced ovarian reserve, 52  
 salpingectomy as, 52  
 TVOR and, 105
- hydroxy-ethyl starch (HES), 94  
 hypotension, 100  
 hysterosalpingo-contrast-sonography  
 (HyCoSy), 59  
 fallopian tube assessment and,  
 155–6  
 performance of, 59  
 purpose and function of, 59  
 risks of, 59  
 hysterosalpingogram (HSG), 40  
 with OSCM, 57  
 performance of, 57  
 purpose and function of, 56–7  
 risks of, 57–8  
 SIN, 57  
 tubal flushing at, 57  
 with WSCM, 57
- hysteroscopic proximal intratubal  
 occlusion, 81
- hysteroscopic surgery  
 for IUAs, 41–2, 44  
 second-look, 44
- hysteroscopy, 161
- ICMART. *See* International  
 Committee for Monitoring  
 Assisted Reproduction
- ICSI. *See* intracytoplasmic sperm  
 injection
- IMSI. *See* intracytoplasmic  
 morphologically selected  
 sperm injection
- in vitro* fertilization (IVF). *See also*  
 assisted reproduction  
 treatment; Complementary  
 and Alternative medicine;  
 infection; intramural fibroids;  
 marketing; quality  
 management system
- adenomyosis and, 29  
 in ambulatory settings, 97  
 birth of Louise Brown, 1  
 CHM and, 46–7  
 Cooke and, personal history of, 1–4  
 in Costa Rica, 3  
 costs of, 6  
 embryo cryopreservation, 2  
 future of, 209, 211  
 under Human Fertilisation and  
 Embryology Act, 2  
 ICSI in, 2  
 laparoscopic egg retrieval, 1–2  
 OHSS, 3  
 SET in, 2–3  
 in UK, 11  
 workflow chart, 70
- in vitro* fertilization (IVF) failures,  
 management plans for  
 alcohol consumption and, 159  
 BMI factors, 159  
 embryo quality and selection,  
 improvements to, 160–1  
 through AH, 160  
 through blastocyst transfer, 160  
 through PGS, 160–1  
 endometrial receptivity and, 161  
 ET and, 161  
 gamete donation and, 163  
 hydrosalpinges removal and, 162  
 clinical trials, 162

- hysteroscopy for, 161
- intra-cavity lesions, 161–2
  - endometrial polyps, 161
  - IUAs, 161–2
  - submucous fibroid, 161
  - uterine septum, 161
- multi-disciplinary approach to, 159–60
  - through lifestyle changes, 159
  - ovarian stimulation protocol, 160
  - with sperm DNA fragmentation, 160
- myometrial pathology, 162
  - adenomyosis, 162
  - intramural fibroids, 162
- in poor responders, 160
- smoking as factor in, 159
- surrogacy and, 163
- incubator failure
  - equipment malfunction, 129–30
    - identification of, 129–30
    - prevention strategies, 129
    - resolution of, 130
  - flowchart for, 130
  - gas supply failure, 127–8
    - identification of, 127–8
    - prevention of, 127
    - resolution of, 128
  - power supply failure, 128–9
    - identification of, 128–9
    - prevention strategies, 128
    - resolution of, 129
- infection, in IVF laboratories
  - Candida albicans*, 144–5
  - consequences of, 145
  - Escherichia coli*, 144–5
  - identification of, 144–5
  - prevention of, 145–7
  - resolution of, 145, 146
    - through cleaning solutions, 145
  - sources of, 143–4
    - from bacteria, 144–5
    - from environmental contaminant, 143–4
    - from follicular aspirates, 144
    - from fungus, 144
    - microbial, 146
    - in seminal fluid, 143
    - from staff, 143
  - types of, 143, 144
- infertility. *See also* hydrosalpinges
  - adenomyosis and, 28
  - WHO task force on, development of, 1
- infertility centers. *See* financial models; marketing
- informed consent, 192
- inositol, 17
- Internal Quality Control (IQC), 178
- International Committee for Monitoring Assisted Reproduction (ICMART), 2
- Intra Uterine Insemination (IUI), 46–7
- intracytoplasmic morphologically selected sperm injection (IMSI), 171
- intracytoplasmic sperm injection (ICSI), 2, 165–6
- intramural fibroids
  - ART influenced by, 8
  - health outcomes, 7
  - IVF failure and, 162
  - management approaches, in clinical practice, 9–10
  - mechanism of action for, 9
- myomectomy for, 9
  - laparoscopy for, 9
  - laparotomy for, 9
  - NNT assessment for, 9
- non-cavity distorting, 8
- prevalence of, 7
- review data on, 7–8
- size of, 8–9
- submucosal, 7, 9
- intrauterine adhesions (IUAs)
  - causes of, 40
  - clinical features, 40
  - defined, 40
  - diagnosis of, 40–1
    - with HSG, 40
    - with hysteroscopy, 41
    - with ultrasound, 40–1
  - ET and, 44
  - future pregnancies with, management of, 44
  - incidence rates for, 40
  - IVF failure and, 161–2
  - postoperative assessment of, 44
    - of endometrial function, 44
    - with second-look hysteroscopy, 44
  - prevention strategies, 42–3
    - with amnion graft, 43
    - Cook intrauterine balloon, 43
    - Foley catheter with balloon, 42
    - hyaluronic acid, 43
    - IUCDs, 42
  - thin endometrium from, 76, 77
  - treatment strategies, 41–2
    - with antibiotics, 43
    - with estrogen therapy, 43–4
    - with Foley balloon therapy, 42
    - with hysteroscopic surgery, 41–2, 44
  - regeneration of endometrium, 43–4
  - ultrasound for, 155
- intrauterine contraceptive devices (IUCDs), 42
- intrauterine fluid issues
  - aetiology, 79
  - causes of, 79
  - clinical implications for, 79
  - epidemiology, 79
  - ET and, 79, 82, 83
  - management of, 81–3
    - with AMH, 81
    - through clinical trials, 83
  - health outcomes, 81
  - pathophysiology, 79–81
    - in animal studies, 80
    - with hydrosalpinges, 79–81
  - pelvic anatomy scans for, 81
  - TVS for, 80
  - 3D TVS, 80
- intrauterine synaechiae, 40
- IQC. *See* Internal Quality Control
- IUAs. *See* intrauterine adhesions
- IUCDs. *See* intrauterine contraceptive devices
- IUI. *See* Intra Uterine Insemination
- IVF. *See in vitro* fertilization; *in vitro* fertilization failures
- JZ hyperplasia, 28, 29, 30
- ketoconazole, 95
- key performance indicators (KPI)
  - ACE, 68
  - control charts and, 66
  - control data, 67
  - EQA programmes, 72
  - ESHRE recommendations, 66, 67
  - establishment of, 66–70
  - IVF workflow chart, 70
  - management of, 66–70
  - for oocyte cryopreservation, 134
  - preparation process flowchart, 69–70
  - in QMS, 178
  - red-alerts, 70–2
    - consumables and, 72
    - culture medium, 72
    - general clinics and lab work, 71
    - laboratory equipment and, 71–2
    - new processes, 70–1
    - staff response to, 72
    - VOC levels, 71
  - sperm production processes, 69–70
  - TQI approach and, 67–9
  - troubleshooting process flowchart, 71
- laparoscopic egg retrieval, 1–2
- laparoscopic tubal ligation, 81
- laparoscopy
  - for myomectomy, 9
  - for ovarian tissue cryopreservation, 21, 22



## Index

- tissue replacement in, 22  
 laparotomy, for myomectomy, 9  
 L-Arginine, 77  
 letrozole, 26, 95  
 levonorgestrel, 29  
 LH. *See* luteinizing hormone  
 limited follicular recruitment.  
     *See* follicular recruitment  
 long agonist stimulation protocols, 11  
 'lost' embryos, 138–42  
     from accidents, 141  
     causes of, 139  
     from failure to follow processes, 140, 141  
     from moving between dishes, 138–41  
 luteal phase support  
     audits for, 90  
     donor oocyte cycles, 89  
     FET and, 89, 90  
     historical background for, 86  
     hormones used as, 87  
         estrogen, 89  
         GnRH agonists, 89, 90  
         hCG, 86, 89  
         progesterone preparations, 86–9  
         protocols for, 89–90  
     LH, 86  
     mechanisms for, 86  
     OHSS and, 86–9, 94  
     research for, 90  
 luteinizing hormone (LH), 86  
 MAC. *See* monitored anaesthesia care  
 magnetic activation cell sorting (MACS), 171  
 magnetic resonance imaging (MRI), of  
     adenomyosis, 28  
 males  
     aging for  
         ART consultations influenced by, 32  
         paternity influenced by, 33  
         sperm quality and, 32–4  
     ART and  
         age criteria for, 32  
         clinical reasons for, 32  
         equipment for, 34  
         information sheets for, 34  
         'must have' protocols, 34  
         strategies for, 34  
     fertility preservation methods  
         for boys, 26  
         for men, 26  
     TFF and, 165–6, 167  
 manual aspiration pump, 109  
 machine failure actions, 109  
 marketing, of IVF  
     assessments of markets, 186  
     branding in, 186–7  
     buyer behaviour and, 189, 190  
     control evaluation in, 190  
     customer service and, 188–9  
     defined, 186  
     marketing plans, 186–7  
         clinic location, 187, 190  
         pricing strategies, 187  
         for products and services, 187  
     positioning in, 186–7  
     promotion strategies, 187–8  
         in digital media, 187–8  
         in written media, 188  
     segmentation in, 186  
     staff for, 188–9  
     target markets, 186  
 metformin, 94  
 methylprednisolone, 95  
 mobile ovaries, 104  
 mock ET, 121  
     stylet use, 121  
     tenaculum use, 121  
     timing of, 121  
 monitored anaesthesia care (MAC),  
     98–9  
 monofollicular recruitment, 110  
 Mortimer, David, 66  
 Mortimer, Sharon, 66  
 mosaicism, 150–1  
 MRI. *See* magnetic resonance imaging  
 myomectomy, for intramural fibroids,  
     9  
     laparoscopy for, 9  
     laparotomy for, 9  
     NNT assessment for, 9  
 National Institute of Health Research  
     (NIHR), 191  
 nausea and vomiting, 100  
 necrospemia, 165  
 next generation sequencing (NGS), 150  
 NIHR. *See* National Institute of Health  
     Research  
 number needed to treat (NNT), for  
     myomectomy, 9  
 nurses. *See* research nurses  
 OHSS. *See* ovarian hyperstimulation  
     syndrome  
 oil-soluble contrast media (OSCM), 57  
 oligoasthenoatozoospermia, 165  
 oocyte cryopreservation  
     downward trends for, investigation  
         of, 134  
         bias in, 134  
         data volume, 134  
         embryo demographics, 135  
         laboratory changes, 135  
         patient demographics, 134  
         upstream factors in, changes to,  
             135  
     for female cancer patients, 25–6  
     KPI for, 134  
     letrozole and, 26  
     ovarian tissue cryopreservation  
         compared to, 19  
     poor survival after  
         corrective actions, 135–7  
         culture conditions and, 133  
         environmental issues and, 133  
         equipment issues and, 133  
         freezing/thawing issues, 132  
         human factors for, 133–4  
         investigation of, 132  
         operator protocols as factor in,  
             132–3  
         patient history as factor in, 132  
         preventative measures for, 135–7  
         processes and factors for, 133  
         reporting considerations for, 134  
     semen sample production failure  
         and, 126  
     success rates for, 26  
 oocyte retrieval. *See also* transvaginal  
     ultrasound-directed oocyte  
     retrieval  
     with CAM, 49  
     donor, 89  
     with endometrioma, 38  
     'lost' embryos in, 138–42  
         from accidents, 141  
         causes of, 139  
         from failure to follow processes,  
             140, 141  
         from moving between dishes,  
             138–41  
     organizational guidelines for, 115  
 OSCM. *See* oil-soluble contrast media  
 ovarian follicle stimulation, 49  
     poor response to, 110  
     management of, 111  
 ovarian hyperstimulation syndrome  
     (OHSS), 3, 11, 92  
     AMH and, 92  
     anaesthesia use and, 98, 100  
     coasting and, 12, 94  
     controlled ovarian stimulation, 92–4  
         coasting in, 94  
         with FSH, 93–4  
         with GnRH antagonists, 92–4  
         with hCG, 93–4  
         in luteal phase support, 94  
     cryopreservation and, 12  
         of embryos, 94  
     luteal phase support and, 86–9  
     pharmacologic interventions, 94–5  
         albumin, 95  
         comparisons between, 95  
         dopamine agonists, 94  
         HES, 94  
         IV calcium infusions, 95

- low-dose aspirin, 94
- metformin, 94
- prediction of, 92
  - demographics in, 92
  - ovarian reserve markers, 92
  - ovarian response parameters, 92
- preventative measures, 92–5
- ovarian reserve. *See also* reduced ovarian reserve
- PGD/PGS management and, 151
- ovarian reserve markers, 92
- ovarian response parameters, 92
- ovarian stimulation protocols
  - antagonist, 11
  - dosage regimes, 12–13
    - for GnRH, 12–13
    - SOP guidelines, 12
  - FSH in, 11–12
  - IVF failure and, 160
  - long agonist, 11
  - protocol selection, 12
- ovarian tissue cryopreservation
  - for cancer patients
    - for girls, 25
    - for women, 25
  - consent for, 21
  - criteria for, 20
    - fertility risk assessments, 21–2
    - patient selection, 20–2
  - development of, 19–20
  - documentation for, 22
    - audits of, 23
  - embryo cryopreservation compared to, 19
  - global availability of, 22
  - key features of, 19–20
  - laparoscopy for, 21, 22
    - tissue replacement in, 22
  - oocyte cryopreservation compared to, 19
  - options in, 19
  - primordial follicles in, 25
  - radiotherapy risks, 22
- ovaries, assessment of, 156–7
  - AFC, 156
  - follicle count, 156–7
- ovary transposition, 25
- pain management, anaesthesia use and, 100
- patient engagement teams (PETs), 195
- patient’s perspective, on assisted reproduction
  - on egg collection day, 5
  - on ET, 5–6
  - IVF costs and, 6
- PB biopsy. *See* polar body biopsy
- pelvic anatomy scans, 81
- pelvic inflammatory disease (PID), 61
  - TVOR and, 102
- penile vibratory stimulation (PVS), 125
- pentoxifylline, 77
- peri-conception issues, 167
- PETs. *See* patient engagement teams
- PFF. *See* previous fertilisation failure
- PGD. *See* preimplantation genetic diagnosis
- PGS. *See* preimplantation genetic screening
- PID. *See* pelvic inflammatory disease
- platelet-rich plasma (PRP), 78
- polar bodies, FF and, 165
- polar body (PB) biopsy, 148–9
- poor embryo development, 169–73
  - aneuploidy oocytes and, 170–1
  - causes of, 170–2
  - culture media integrity, 171–2
  - definition of, 169–70
  - IMSI and, 171
  - MACS and, 171
  - reprotoxicity and, 171–2
  - sperm integrity and, 171
  - sperm selection methods, 171
  - in subsequent cycles, prediction of, 172–3
- poor responders, to GnRH therapy
  - adjuvant therapies for, 16–17
    - androgens in, 16–17
    - growth hormones in, 17
  - Bologna Criteria for, 14, 15
  - counselling for, 17–18
    - for couples, 17
  - drop-out rates for, 16
  - ESHRE definitions for, 14
  - etiology of, 14
  - FSH doses for, 15, 16
  - heterogeneity of, 14
  - IVF failure in, 160
  - PGD/PGS management and, 151
  - predictive tests for, 14–15
  - prevalence of, 14
  - previous cycle outcomes, 15
  - reduced ovarian reserve and, 15
  - stimulation protocols in, 15–16
    - corifollitropin alfa in, 16
    - down-regulation, 16
    - Elonva Flare in, 16
    - unexpected, 15
- power supply failure, in incubators, 128–9
  - identification of, 128–9
  - prevention strategies, 128
  - resolution of, 129
- pregnancy
  - adenomyosis, 29
  - anaesthesia use and, 98
  - CPR, 47
  - with endometrioma, 38
  - IUAs and, 44
- preimplantation genetic diagnosis (PGD)
  - biopsy procedures, 148–9
    - blastomere, 149
    - PB, 148–9
    - trophectoderm, 149
  - diagnostic techniques, 149–50
    - for chromosome disorders, 150
    - for genetic disorders, 149–50
    - with NGS, 150
  - early history of, 148
  - indications of, 148
  - management and policy strategies, 151–2
    - for inconclusive results, 152
    - with ovarian reserve issues, 151
    - with PGS, 151–2
    - with poor responders, 151
    - with untested cryopreserved embryos, 151
  - mosaicism and, 150–1
  - non-invasive sampling, 149
  - quality control standards in, 151
- preimplantation genetic screening (PGS)
  - advanced maternal age and, 148
  - biopsy procedures, 148–9
    - blastomere, 149
    - PB, 148–9
    - trophectoderm, 149
  - diagnostic techniques, 149–50
    - for chromosome disorders, 150
    - for genetic disorders, 149–50
    - with NGS, 150
    - with PGS indications, 150
  - early history of, 148
  - indications of, 148
  - IVF failure and, 160–1
  - management and policy strategies, 151–2
    - for inconclusive results, 152
    - with ovarian reserve issues, 151
    - with PGD, 151–2
    - with poor responders, 151
    - with untested cryopreserved embryos, 151
  - mosaicism and, 150–1
  - non-invasive sampling, 149
  - quality control standards in, 151
- preparation process flowcharts, KPI, 69–70
- previous fertilisation failure (PFF), 165
- primordial follicles, 25
- Pringle, Fiona, 207–8
- progesterone, 86–9
  - adequate follicular recruitment and, 111–12
  - synthetic, 86
- propofol, 99

## Index

- PRP. *See* platelet-rich plasma  
 PVS. *See* penile vibratory stimulation
- QMS. *See* quality management system  
 quality control, 178  
 quality management system (QMS), in  
   IVF, 175–9  
   accreditation, 179  
   audits of, 178  
   clinic documents, 176, 177  
   in clinical settings, 175  
   components of, 174  
   defined, 174–5  
   document control, 176–8  
   equipment in, 176–7  
   feedback in, 178–9  
   incident reporting in, 178  
   KPIs for, 178  
   manuals, 176  
   non-conformities in, 178  
   patient satisfaction for, 178–9  
   personnel and, 175–6  
     satisfaction of, 178–9  
   policy objectives of, 176  
   for premises, 176–7  
   problem analysis, 179  
   quality control, 178  
   third-party agreements and, 176  
   validation of, 178  
 quinagolide, 94
- radiation-induced uterine damage, 76  
 radiotherapy risks, 22  
 randomised control trials (RCTs), 192  
 reprotoxicity, 171–2  
 reduced ovarian reserve, 15  
   hydrosalpinx treatment strategies  
     with, 52  
 research nurses  
   in case studies  
     procedures, 192  
     research recruitment in, 193  
     during setup, 191–2  
   data collection by, 192–3  
   data input by, 193  
   in gatekeeper principle, 194  
   informed consent and, 192  
   in national research agenda, 191  
   potential barriers, 195  
   in RCTs, 192  
   in referral process, 193–5  
   role and responsibilities of, 191, 192  
   safety reporting by, 193  
 retrograde ejaculation, 125  
 revenues. *See* financial  
   models
- safety reporting, 193  
 saline infusion sonography (SIS), 41  
   3D SIS, 41
- salpingectomy, 52  
   for intrauterine fluid issues, 81  
 salpingitis isthmica nodosum (SIN), 57  
 salpingoscopy. *See* fallopscopy  
 salpingostomy, 81  
 second-look hysteroscopy, 44  
 sedation, ET under, 121  
 semen samples, failure to produce,  
   123–4  
   aetiology of, 123–3  
   ejaculatory function and  
     normal, 123  
     retrograde, 125  
   risk factors for, 123  
 erectile function and  
   normal, 123  
   risk factors for, 123  
 management strategies, 124–6  
   with drug treatment, 125  
   with electroejaculation, 125  
   pre-treatment risk assessment,  
     124  
   with PVS, 125  
   sample production at home, 124  
   timing of intercourse, 124–5  
 prevention strategies, 124–6  
   audiovisual aids, 124  
   cycle cancellation, 126  
   oocyte cryopreservation, 126  
   partner support as part of, 124  
   sperm cryopreservation, 124  
   risk factors for, 123–3  
   SSR and, 125–6  
   urinary sperm retrieval, 125  
 Septrafilm, 43  
 sequential culture media  
   blastocyte-stage transfer, 64  
   defined, 63  
   single-step compared to, 63–4  
 SET. *See* single embryo transfer  
 sildenafil, 77, 125  
 SIN. *See* salpingitis isthmica nodosum  
 single embryo transfer (SET), 2–3  
 single-step culture media  
   blastocyte-stage transfer, 64  
   defined, 63  
   sequential compared to, 63–4  
 SIS. *See* saline infusion sonography  
 Smith, Kevin, 34  
 smoking, IVF failure and, 159  
 sperm cryopreservation, 124  
 sperm DNA fragmentation, 160  
 sperm donors, age guidelines for, 33–4  
 sperm integrity, 171  
 sperm production processes, KPI,  
   69–70  
 sperm quality, aging and, 32–3. *See also*  
   semen samples  
   child health and development, 33–4  
   DNA damage and, 32–3
- SSR. *See* surgical sperm recovery  
 Steptoe, Patrick, 118  
 stimulation protocols, 15–16  
   corifollitropin alfa in, 16  
   down-regulation, 16  
   Elonva Flare in, 16  
   endometrioma treatment options  
     and, 37  
   ovarian follicles, 49  
 stylets, 121  
 subfertility, causes of, 97  
 submucous fibroids, 161  
 surgical sperm recovery (SSR), 125–6  
 surrogacy  
   early development of, 3  
   IVF failure and, 159  
 synthetic progesterone, 86
- tadalafil, 125  
 tenaculums, 121  
 TFF. *See* total fertilisation failure  
 thin endometrium. *See also*  
   endometrial thickness  
   Asherman's syndrome and, 76  
   causes of, 76  
   iatrogenic, 76  
   idiopathic, 76  
   IUA, 76, 77  
   Turner's syndrome, 76  
 COH and, 76  
 definition, 74  
 FET and, 76–7  
 incidence rates, 74  
 management of, 76–8  
   with endometrial perfusion  
     therapies, 77  
   with estrogen, 77  
   with GcSF, 78  
   with GnRH agonists, 77  
   with HGC, 77  
   with PRP, 78
- 3D SIS. *See* three-dimensional saline  
   infusion sonography  
 3D TVS. *See* three-dimensional  
   transvaginal ultrasound  
 3D ultrasound  
   fallopian tube assessment with,  
     155–6  
   HyCoSy and, 155–6  
   with hydrosalpinges, 156  
   for patency, 155–6  
   historical background of, 153  
   ovary assessment with, 156–7  
   AFC, 156  
   follicle count, 156–7  
   uterine assessment with, 153–5  
     of acquired anomalies, 155  
     of congenital anomalies, 154–5  
     of endometrium, 153–4  
     of sub-endometrium, 153–4



- three-dimensional saline infusion sonography (3D SIS), 41
- three-dimensional transvaginal ultrasound (3D TVS), 41, 80
- TMET. *See* transmyometrial embryo transfer
- total fertilisation failure (TFF), 165–6
- Total Quality Improvement (TQI) approach, 67–9
- transmyometrial embryo transfer (TMET), 121
- transvaginal aspiration, 81
- transvaginal hydrolaparoscopy. *See* fertiloscopy
- transvaginal ultrasound (TVS)
  - for EMT, 80
  - for intrauterine fluid issues, 80
  - 3D TVS, 80
  - 2D TVS, 40–1
  - 3D TVS, 41, 80
- transvaginal ultrasound-directed oocyte retrieval (TVOR)
  - aspiration procedures, 103–4
  - blood vessel identification, 104–5
  - complications from, 104
    - early, 115–17
    - for egg collection, 114–15
    - late, 117
    - patient selection as factor in, 114
    - prevalence of, 114
    - procedural, 114
    - rates of, 102
    - risk management in, 117
  - egg collection and, 104, 114–15
  - electric oocyte aspiration pumps and functions of, 108
  - installation and set-up, 107–9
  - machine failure actions, 109
  - possible issues/solutions for, 108–9
  - with empty follicle syndrome, 105
  - endometriosis and, 105
  - endometriotic cysts and, 102
  - follicles and, 104–5
  - follicular flushing and, 104
  - hydrosalpinx, 105
  - with large uterus, 105
  - manual aspiration pumps and, 109
  - machine failure actions, 109
  - ovary location and, 104
  - mobile ovaries, 104
  - above vaginal fornices, 104
- PID and, 102
- preliminary steps of, 102–3
  - comorbidities and, 102–3
  - transvaginal probe, 103
  - urination procedures, 103
  - temperature control with, 104
- trophectoderm biopsy, 149
- troubleshooting process flowchart, KPI, 71
- tubal assessment, 58. *See also* hysterosalpingogram
- CAT in, 60–1
- PID and, 61
- comparisons between tests, 61
- falloposcopy for, 60
- performance of, 60
- risks with, 60
- fertiloscopy for, 59–60
- performance of, 60
- risks with, 60
- HyCoSy for, 59
- performance of, 59
- purpose and function of, 59
- risks of, 59
- infertility rates and, 55
- laparoscopy and dye for, 58–9
- function and purpose of, 58
- performance of, 58–9
- risks of, 59
- methods of, 56–61
- patency, of Fallopian tubes, 55
- timing of, 55–6
  - with no history of tubal assessments, 56
  - with tubal blockage risk factors, 55
  - with un-investigated tubal abnormalities, 55, 56
  - with uterine abnormalities, 55
- tubal disease. *See* hydrosalpinges
- Turner’s syndrome, 76
- TVOR. *See* transvaginal ultrasound-directed oocyte retrieval
- TVS. *See* transvaginal ultrasound
- two-dimensional transvaginal ultrasound scan (2D TVS), 40–1
- UCA. *See* utero-cervical angle
- UK. *See* United Kingdom
- ultrasound. *See also* 3D ultrasound; transvaginal ultrasound
  - for adenomyosis, 155
  - early history of, 1
  - for ET, 120
  - for IUAs, 40–1, 155
    - SIS, 41
    - 2D TVS, 40–1
    - 3D TVS, 41
  - unilateral endometrioma, 36
  - United Kingdom (UK)
    - Human Fertilisation and Embryology Act, 2
    - IVF centres in, 11
  - urinary retention, 100
  - urinary sperm retrieval, 125
  - utero-cervical angle (UCA), 119
  - uterus, assessment of
    - IVF failure and, 161
    - with 3D ultrasound, 153–5
      - for acquired anomalies, 155
      - for congenital anomalies, 154–5
      - of endometrium, 153–4
      - of sub-endometrium, 153–4
    - TVOR and, 105
  - vaginal fornices, 104
  - vardenafil, 125
  - vitamin E, 77
  - volatile organic compounds (VOCs), 71
- Warnock, Mary, 3
- water-soluble contrast media (WSCM), 57
- WHO. *See* World Health Organisation
- whole system Traditional Chinese Medicine (WS-TCM), 48
- women, with cancer, fertility preservation methods for, 24–6
  - with GnRH agonists, 24–5
  - through oocyte cryopreservation, 25–6
  - through ovarian tissue cryopreservation, 25
  - through ovary transposition, 25
- World Health Organisation (WHO), task force on infertility, development of, 1
- WSCM. *See* water-soluble contrast media
- WS-TCM. *See* whole system Traditional Chinese Medicine